

ASX Announcement 5 October 2023

## **ANNUAL GENERAL MEETING DATE**

**Optiscan Imaging Limited (ASX: OIL)** ('the Company' or 'Optiscan') advises that in accordance with ASX Listing Rule 3.13.1 its Annual General Meeting ("AGM") will be held on Thursday, 23 November 2023. Accordingly, for the purposes of ASX Listing Rule 3.13.1 and Clause 15.3 of its Constitution, the Company advises that the closing date for nominations for the position of Director is 5:00pm (AEDT) on 12 October 2023.

The Company notes that the deadline for nominations for the position of Director is separate to voting on the election of Director. Details of the Directors nominated to be elected will be provided in the Company's Notice of AGM in due course.

- ends -

This announcement has been authorised for release by the Board of Optiscan.

## For investor queries, please contact:

Dr. Camile Farah

Chief Executive Officer & Managing Director – Optiscan Imaging Ltd

E: cfarah@optiscan.com

## **About Optiscan**

Optiscan Imaging Ltd (ASX:OIL) is a global leader in the development, manufacturing, and commercialisation of confocal endomicroscopic imaging technologies for medical, translational and pre-clinical applications. Our technology enables real-time, non-destructive, 3D, *in-vivo* imaging at the single-cell level.

We are driven by developing technology and its use to give healthcare providers and researchers the highest quality real-time microscopic imaging tools to enable the early detection and management of disease, improve patient outcomes, and reduce the high cost of curative medicine and associated procedures.

Our patent-protected proprietary technology, using specially miniaturised componentry, has created a pen-sized digital microscope, which can be used on any tissue it contacts to produce high resolution digital pathology images for cancer diagnosis and surgical margin detection in real-time. The aim of our technology development is for earlier diagnosis and subsequent treatment of cancerous tumours with expected associated improved patient outcomes.

P: (61 3) 9538 3333

A: 16 Miles St, Mulgrave VIC 3170, Australia

W: www.optiscan.com